The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to ...

Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results demonstrating its lead compound, Telomir-1, significantly reduced react ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Presidents' Day is officially behind us and while most of Monday's epic deals have expired, I've spotted a handful of sales you can still get. There's no guarantee these deals will last through the ...

Telomir Pharmaceuticals (TELO) announced results from its recent preclinical studies conducted in human retinal cell lines. These studies ...

Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects people over the age of 50. AMD is a leading cause of vision loss in people over 50.

Clearside Biomedical, Inc. (NASDAQ:CLSD), currently valued at $81.15 million, is a biotechnology company focused on developing innovative therapies for blinding eye diseases using its proprietary SCS ...

Cataracts, dry eyes, glaucoma and other eye problems become more common with age. But these can be treated — and sometimes ...

Although AI shows significant promise in diagnosing and managing age-related macular degeneration, its efficacy is reduced by ...

Ophthalmologists must take measures to avoid misdiagnosing age-related macular degeneration and consider mimics of the ...